Upadacitinib hemihydrate
Spezifikationen
2050057-56-0CAS-Nummer
bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrateIUPAC-Name
C34H40F6N12O3Chemische Formel
778.8 g/molMolekulargewicht
Upadacitinib hemihydrate; 2050057-56-0; RINVOQ LQ; NEW4DV02U5; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-E)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-; RefChem:1100658; Rinvoq; (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate(2:1); Upadacitinib hydrate (JAN); (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate; UPADACITINIB HYDRATE [JAN]; upadacitinib hydrate; Rinvoq (TN); UNII-NEW4DV02U5; Upadacitinib (as hemihydrate); CHEMBL5315119; EBC-134021; UPADACITINIB HEMIHYDRATE [WHO-DD]; (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;hydrate; AC-37935; AS-97188; D11048; H53955; (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1); 1831899-73-0; bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrate; rel-(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate(2:1)Synonyme
Produkte, die Upadacitinib hemihydrate enthalten
린버크서방정30밀리그램(유파다시티닙반수화물)린버크서방정15밀리그램(유파다시티닙반수화물)RINVOQ 30 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 30 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 15 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 45 mg, comprimé à libération prolongéeRINVOQ 30 mg, comprimé à libération prolongéeRINVOQ 15 mg, comprimé à libération prolongéeUpadacitinib hemihydrate CAS:2050057-56-0Upadacitinib HemihydrateUpadacitinib Hemihydrate
Seite 1 von 2
Unternehmen, die Upadacitinib hemihydrate verkaufen
AD
Abbvie Deutschland GmbH & Co. KGGermanySD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaHH
HANGZHOU HONGQIN PHARMTECH CO.,LTDChinaAH
Anhui Haikang Pharmaceutical Co., Ltd.ChinaWH
Wuxi Hexia Chemical CompanyChinaZH
Zhejiang Huayi Pharmaceutical Co., Ltd.China한국
한국애브비(주)Republic of KoreaBS
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.ChinaJX
Jinan Xinnuo Pharmaceutical Co., LtdChina